Publications

Our scientific publications in high-quality journals reflect the quality of the innovative research in Entasis’ laboratories.

Search by Program

Yang Q, Xu Y, Jia P, Zhu Y, Zhang J, Zhang G, Deng J, Hackel M, Bradford PA, and Reinhart H

In vitro activity of sulbactam/durlobactam against clinical isolates of Acinetobacter baumannii collected in China

Journal of Antimicrobial Chemotherapy (2020)

Sagan O, Yakubsevitch R, Yanev K, Fomkin R, Stone E, Hines D, O’Donnell J, Miller A, Isaacs R, and Srinivasan S

Pharmacokinetics and tolerability of intravenous sulbactam-durlobactam with imipenem-cilastatin in hospitalized adults with complicated urinary tract infections, including acute pyelonephritis

Antimicrobial Agents and Chemotherapy (2020)

McLeod SM, Moussa SH, Hackel MA, and Miller AA

In vitro activity of sulbactam-durlobactam against Acinetobacter baumannii-calcoaceticus complex isolates collected globally from 2016-2017

Antimicrobial Agents and Chemotherapy (2020)

O’Donnell J, Preston RA, Mamikonyan G, Stone E, and Isaacs R

Pharmacokinetics, safety, and tolerability of intravenous durlobactam and sulbactam in subjects with renal impairment and healthy matched control subjects

Antimicrobial Agents and Chemotherapy (2019)

Miller AA, Traczewski MM, Huband MD, Bradford PA, Mueller JP

Determination of MIC quality control ranges for the novel gyrase inhibitor, zoliflodacin

Journal of Clinical Microbiology (2019)

Barnes MD, Kumar V, Bethel CR, Moussa SH, O’Donnell J, Rutter JD, Good CE, Hujer KM, Hujer AM, Marshall SH, Kreiswirth BN, Richter SS, Rather PN, Jacobs MR, Papp-Wallace KM, van den Akker F, and Bonomo RA

Targeting multidrug-resistant Acinetobacter spp.: sulbactam and the diazabicyclooctenone β-lactamase inhibitor ETX2514 as a novel therapeutic agent

mBio (2019)

Iyer R, Moussa S, Tommasi R, and Miller A

Role of the Klebsiella pneumoniae TolC porin in antibiotic efflux

Research in Microbiology (2019)